Abstract
Intensive glycemic control and aggressive glycated hemoglobin targets <7.0% have failed to show an improvement in cardiovascular mortality. Repetitive and severe hypoglycemic episodes with intensive glucose-lowering therapy may be a major factor in the failure to show cardiovascular benefit in diabetic patients. In this article, the cardiovascular effects of hypoglycemia, and the trials with an intensive glucose-lowering strategy that have studied microvascular and macrovascular complications are discussed. The current non-insulin drugs, which do not induce hypoglycemia, available for the treatment of diabetes and their cardiovascular impacts are clarified.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
